The US hemp industry has successfully bought itself some additional time to find a permanent solution to the incoming federal ban.
Senate leaders moved to include a short delay to the sweeping hemp ban into a must-pass spending bill, giving some, but not all hemp-derived products until December 11 rather than November 12 before they’re pulled from shelves.
On 2 August, the leaders of the Senate Appropriations Committee, Chair Susan Collins and Vice Chair Patty Murray, released the text of a continuing resolution, the Continuing Appropriations and Extensions Act, 2027, to keep federal agencies funded through 11 December, past the end of the fiscal year on 30 September.
Under a provision titled ‘Section 781 Extension’ is language stating that until 11 December the November ban ‘shall only apply’ to certain synthetic cannabinoid products, holding off the recriminalisation of the wider hemp market that had been due on 12 November.
Specifically, this applies only to naturally- derived hemp THC products, including the drinks and full-spectrum CBD lines that are also under threat from the wider looming restrictions.
Synthetic cannabinoids, defined in the bill as ‘not capable of being naturally produced by a Cannabis sativa L. plant’ such as some delta-8 THC, would still be recriminalised on 12 November as originally planned.
READ MORE…
While the extension only gives these products another few weeks, the industry is hoping this will be enough time for a more permanent fix to be included in the next must-pass funding bill, due on December 11.
As we reported last week, the Lawful Hemp Protection Act from Representatives Andy Barr and Angie Craig, which would repeal the ban outright and regulate the products instead, is now making its way through the legislative process.
A Senate companion bill is expected from Senators Tim Sheehy and Amy Klobuchar, while Representative James Comer is circulating a rival delay-and-regulate proposal.
“As Mark Twain might have said, the reports of hemp’s death have been greatly exaggerated,’ said Jonathan Miller, general counsel of the US Hemp Roundtable, calling the resolution ‘a landmark victory for the hemp industry, our biggest win since the 2018 Farm Bill’.
He cautioned that ‘our work is not done’, with the industry now pushing to hold the language through the House and Senate votes and to secure a fuller fix by the December funding deadline.
The White House has also entered the debate. President Trump has repeatedly urged Congress to preserve access to full-spectrum CBD while restricting products that ‘pose health risks’, and his Office of Management and Budget has pressed House Speaker Mike Johnson to ‘ensure the fair treatment of hemp products’. In April the administration launched a Medicare initiative covering up to US$500 of hemp-derived products a year for eligible patients.
The hemp beverage sector, among the fastest-growing corners of the market, was quick to welcome the move.
“The Hemp Beverage Alliance is thrilled the Senate is standing up for responsible hemp beverage suppliers and their supply chain partners,” said Christopher Lackner, founder and president of the trade body, which represents 375 companies across the US and Canada.
“We urge the Senate to quickly pass this legislation and send it to the House for their swift approval as soon as they return.”









